JP5711968B2 - 高エイコサペンタエン酸を生成するためのヤロウィア・リポリティカ(YarrowiaLipolytica)の最適化株 - Google Patents
高エイコサペンタエン酸を生成するためのヤロウィア・リポリティカ(YarrowiaLipolytica)の最適化株 Download PDFInfo
- Publication number
- JP5711968B2 JP5711968B2 JP2010528141A JP2010528141A JP5711968B2 JP 5711968 B2 JP5711968 B2 JP 5711968B2 JP 2010528141 A JP2010528141 A JP 2010528141A JP 2010528141 A JP2010528141 A JP 2010528141A JP 5711968 B2 JP5711968 B2 JP 5711968B2
- Authority
- JP
- Japan
- Prior art keywords
- seq
- gene
- desaturase
- epa
- yarrowia lipolytica
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 235000020673 eicosapentaenoic acid Nutrition 0.000 title claims description 256
- 241000235015 Yarrowia lipolytica Species 0.000 title claims description 182
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 title claims description 20
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 title claims description 20
- 229960005135 eicosapentaenoic acid Drugs 0.000 title claims description 19
- 108090000623 proteins and genes Proteins 0.000 claims description 394
- 210000004027 cell Anatomy 0.000 claims description 149
- 230000014509 gene expression Effects 0.000 claims description 140
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 129
- 229930195729 fatty acid Natural products 0.000 claims description 129
- 239000000194 fatty acid Substances 0.000 claims description 129
- 150000004665 fatty acids Chemical class 0.000 claims description 126
- 102000004169 proteins and genes Human genes 0.000 claims description 121
- 108010073542 Delta-5 Fatty Acid Desaturase Proteins 0.000 claims description 73
- 102100034542 Acyl-CoA (8-3)-desaturase Human genes 0.000 claims description 70
- 238000000034 method Methods 0.000 claims description 68
- 238000004519 manufacturing process Methods 0.000 claims description 67
- 230000015572 biosynthetic process Effects 0.000 claims description 66
- 241000235013 Yarrowia Species 0.000 claims description 60
- 108010022240 delta-8 fatty acid desaturase Proteins 0.000 claims description 55
- 210000002824 peroxisome Anatomy 0.000 claims description 50
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 34
- 230000000813 microbial effect Effects 0.000 claims description 33
- 108010051225 Diacylglycerol cholinephosphotransferase Proteins 0.000 claims description 27
- 102000013444 Diacylglycerol Cholinephosphotransferase Human genes 0.000 claims description 23
- 238000012258 culturing Methods 0.000 claims description 3
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 description 237
- 150000002632 lipids Chemical class 0.000 description 145
- 235000018102 proteins Nutrition 0.000 description 118
- 235000019198 oils Nutrition 0.000 description 102
- 239000003921 oil Substances 0.000 description 101
- 230000000694 effects Effects 0.000 description 89
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 82
- 239000000047 product Substances 0.000 description 68
- 108091026890 Coding region Proteins 0.000 description 67
- 108020004705 Codon Proteins 0.000 description 64
- 102000004190 Enzymes Human genes 0.000 description 63
- 108090000790 Enzymes Proteins 0.000 description 63
- 229940088598 enzyme Drugs 0.000 description 63
- 239000002609 medium Substances 0.000 description 59
- 239000000758 substrate Substances 0.000 description 58
- 235000013305 food Nutrition 0.000 description 55
- 238000006243 chemical reaction Methods 0.000 description 54
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 53
- 101100382243 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) YAT1 gene Proteins 0.000 description 52
- HOBAELRKJCKHQD-UHFFFAOYSA-N (8Z,11Z,14Z)-8,11,14-eicosatrienoic acid Natural products CCCCCC=CCC=CCC=CCCCCCCC(O)=O HOBAELRKJCKHQD-UHFFFAOYSA-N 0.000 description 51
- HOBAELRKJCKHQD-QNEBEIHSSA-N dihomo-γ-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(O)=O HOBAELRKJCKHQD-QNEBEIHSSA-N 0.000 description 51
- 235000001014 amino acid Nutrition 0.000 description 50
- 239000000203 mixture Substances 0.000 description 46
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 45
- 150000001413 amino acids Chemical class 0.000 description 45
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 43
- 239000013612 plasmid Substances 0.000 description 42
- 230000037361 pathway Effects 0.000 description 41
- 101150099000 EXPA1 gene Proteins 0.000 description 40
- 102100029095 Exportin-1 Human genes 0.000 description 40
- 101100119348 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) EXP1 gene Proteins 0.000 description 40
- 101100269618 Streptococcus pneumoniae serotype 4 (strain ATCC BAA-334 / TIGR4) aliA gene Proteins 0.000 description 40
- 108700002148 exportin 1 Proteins 0.000 description 40
- SRBFZHDQGSBBOR-HWQSCIPKSA-N L-arabinopyranose Chemical compound O[C@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-HWQSCIPKSA-N 0.000 description 37
- 108020004414 DNA Proteins 0.000 description 36
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 description 36
- 235000020664 gamma-linolenic acid Nutrition 0.000 description 36
- 235000020665 omega-6 fatty acid Nutrition 0.000 description 35
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 32
- 238000009482 thermal adhesion granulation Methods 0.000 description 32
- SEHFUALWMUWDKS-UHFFFAOYSA-N 5-fluoroorotic acid Chemical compound OC(=O)C=1NC(=O)NC(=O)C=1F SEHFUALWMUWDKS-UHFFFAOYSA-N 0.000 description 31
- 229940012843 omega-3 fatty acid Drugs 0.000 description 31
- 230000001105 regulatory effect Effects 0.000 description 31
- 108010011713 delta-15 desaturase Proteins 0.000 description 30
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 30
- 108700012830 rat Lip2 Proteins 0.000 description 29
- 101100005882 Mus musculus Cel gene Proteins 0.000 description 28
- 101100289046 Mus musculus Lias gene Proteins 0.000 description 28
- 101150091094 lipA gene Proteins 0.000 description 28
- YAFQFNOUYXZVPZ-UHFFFAOYSA-N liproxstatin-1 Chemical compound ClC1=CC=CC(CNC=2C3(CCNCC3)NC3=CC=CC=C3N=2)=C1 YAFQFNOUYXZVPZ-UHFFFAOYSA-N 0.000 description 28
- 229940033080 omega-6 fatty acid Drugs 0.000 description 28
- 230000009466 transformation Effects 0.000 description 28
- 238000013519 translation Methods 0.000 description 28
- 230000014616 translation Effects 0.000 description 28
- 230000001965 increasing effect Effects 0.000 description 27
- 239000002028 Biomass Substances 0.000 description 26
- 238000004458 analytical method Methods 0.000 description 26
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 26
- 125000003729 nucleotide group Chemical group 0.000 description 26
- 239000002773 nucleotide Substances 0.000 description 25
- 108091028043 Nucleic acid sequence Proteins 0.000 description 24
- 150000007523 nucleic acids Chemical group 0.000 description 24
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 21
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 21
- 241001465754 Metazoa Species 0.000 description 21
- 230000006870 function Effects 0.000 description 21
- 230000035772 mutation Effects 0.000 description 21
- 238000003786 synthesis reaction Methods 0.000 description 21
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 20
- 235000016709 nutrition Nutrition 0.000 description 20
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 19
- 108010001348 Diacylglycerol O-acyltransferase Proteins 0.000 description 19
- 102000002148 Diacylglycerol O-acyltransferase Human genes 0.000 description 19
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 19
- 108091081024 Start codon Proteins 0.000 description 19
- 239000012634 fragment Substances 0.000 description 19
- 230000010354 integration Effects 0.000 description 19
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 19
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 18
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 18
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 18
- 101001126533 Arabidopsis thaliana Peroxisome biogenesis factor 10 Proteins 0.000 description 18
- 239000005642 Oleic acid Substances 0.000 description 18
- 238000003209 gene knockout Methods 0.000 description 18
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 18
- 229920001184 polypeptide Polymers 0.000 description 18
- 108090000765 processed proteins & peptides Proteins 0.000 description 18
- 102000004196 processed proteins & peptides Human genes 0.000 description 18
- 238000009472 formulation Methods 0.000 description 16
- 239000003550 marker Substances 0.000 description 16
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 15
- 241000195619 Euglena gracilis Species 0.000 description 15
- 229910052799 carbon Inorganic materials 0.000 description 15
- 235000019387 fatty acid methyl ester Nutrition 0.000 description 15
- 235000013350 formula milk Nutrition 0.000 description 15
- 230000012010 growth Effects 0.000 description 15
- 108020004999 messenger RNA Proteins 0.000 description 15
- 230000006798 recombination Effects 0.000 description 15
- 239000000126 substance Substances 0.000 description 15
- YUFFSWGQGVEMMI-JLNKQSITSA-N (7Z,10Z,13Z,16Z,19Z)-docosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCCC(O)=O YUFFSWGQGVEMMI-JLNKQSITSA-N 0.000 description 14
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 14
- 230000035508 accumulation Effects 0.000 description 14
- 238000009825 accumulation Methods 0.000 description 14
- 244000005700 microbiome Species 0.000 description 14
- 238000013518 transcription Methods 0.000 description 14
- 230000035897 transcription Effects 0.000 description 14
- 208000016444 Benign adult familial myoclonic epilepsy Diseases 0.000 description 13
- 208000016427 familial adult myoclonic epilepsy Diseases 0.000 description 13
- 238000004817 gas chromatography Methods 0.000 description 13
- 235000013372 meat Nutrition 0.000 description 13
- 230000004048 modification Effects 0.000 description 13
- 238000012986 modification Methods 0.000 description 13
- 230000008569 process Effects 0.000 description 13
- 238000012545 processing Methods 0.000 description 13
- 241000894007 species Species 0.000 description 13
- 238000011144 upstream manufacturing Methods 0.000 description 13
- 239000013598 vector Substances 0.000 description 13
- -1 Δ12 desaturase Proteins 0.000 description 13
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 12
- 230000009471 action Effects 0.000 description 12
- 239000003925 fat Substances 0.000 description 12
- 238000000855 fermentation Methods 0.000 description 12
- 230000004151 fermentation Effects 0.000 description 12
- 235000019688 fish Nutrition 0.000 description 12
- ZGNITFSDLCMLGI-UHFFFAOYSA-N flubendiamide Chemical compound CC1=CC(C(F)(C(F)(F)F)C(F)(F)F)=CC=C1NC(=O)C1=CC=CC(I)=C1C(=O)NC(C)(C)CS(C)(=O)=O ZGNITFSDLCMLGI-UHFFFAOYSA-N 0.000 description 12
- 238000003780 insertion Methods 0.000 description 12
- 230000037431 insertion Effects 0.000 description 12
- 239000006014 omega-3 oil Substances 0.000 description 12
- 238000005215 recombination Methods 0.000 description 12
- 230000002829 reductive effect Effects 0.000 description 12
- 238000005809 transesterification reaction Methods 0.000 description 12
- 241000251468 Actinopterygii Species 0.000 description 11
- 108700016155 Acyl transferases Proteins 0.000 description 11
- 102100039239 Amidophosphoribosyltransferase Human genes 0.000 description 11
- 108010039224 Amidophosphoribosyltransferase Proteins 0.000 description 11
- 241000195620 Euglena Species 0.000 description 11
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 11
- 239000002253 acid Substances 0.000 description 11
- 238000005119 centrifugation Methods 0.000 description 11
- 230000006378 damage Effects 0.000 description 11
- 235000019197 fats Nutrition 0.000 description 11
- 238000007429 general method Methods 0.000 description 11
- 239000007788 liquid Substances 0.000 description 11
- 239000012528 membrane Substances 0.000 description 11
- 238000007254 oxidation reaction Methods 0.000 description 11
- 230000014621 translational initiation Effects 0.000 description 11
- 241000196324 Embryophyta Species 0.000 description 10
- 108010087894 Fatty acid desaturases Proteins 0.000 description 10
- 230000001588 bifunctional effect Effects 0.000 description 10
- 230000015556 catabolic process Effects 0.000 description 10
- 235000013339 cereals Nutrition 0.000 description 10
- 238000012217 deletion Methods 0.000 description 10
- 230000037430 deletion Effects 0.000 description 10
- 235000015872 dietary supplement Nutrition 0.000 description 10
- 239000000543 intermediate Substances 0.000 description 10
- 235000013336 milk Nutrition 0.000 description 10
- 239000008267 milk Substances 0.000 description 10
- 210000004080 milk Anatomy 0.000 description 10
- 229910052757 nitrogen Inorganic materials 0.000 description 10
- 102000039446 nucleic acids Human genes 0.000 description 10
- 108020004707 nucleic acids Proteins 0.000 description 10
- 238000005457 optimization Methods 0.000 description 10
- 239000011701 zinc Substances 0.000 description 10
- 102000004539 Acyl-CoA Oxidase Human genes 0.000 description 9
- 108020001558 Acyl-CoA oxidase Proteins 0.000 description 9
- 101000579335 Arabidopsis thaliana Peroxisome biogenesis protein 12 Proteins 0.000 description 9
- 102100027667 Carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase 2 Human genes 0.000 description 9
- 101710134389 Carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase 2 Proteins 0.000 description 9
- 108700010070 Codon Usage Proteins 0.000 description 9
- 108010091086 Recombinases Proteins 0.000 description 9
- 102000018120 Recombinases Human genes 0.000 description 9
- 235000021355 Stearic acid Nutrition 0.000 description 9
- 102000016553 Stearoyl-CoA Desaturase Human genes 0.000 description 9
- HQPCSDADVLFHHO-LTKCOYKYSA-N all-cis-8,11,14,17-icosatetraenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/CCCCCCC(O)=O HQPCSDADVLFHHO-LTKCOYKYSA-N 0.000 description 9
- 235000013351 cheese Nutrition 0.000 description 9
- 230000004927 fusion Effects 0.000 description 9
- 238000002955 isolation Methods 0.000 description 9
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 9
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 9
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 239000008117 stearic acid Substances 0.000 description 9
- 238000006467 substitution reaction Methods 0.000 description 9
- 230000009469 supplementation Effects 0.000 description 9
- 229910052725 zinc Inorganic materials 0.000 description 9
- WYMDDFRYORANCC-UHFFFAOYSA-N 2-[[3-[bis(carboxymethyl)amino]-2-hydroxypropyl]-(carboxymethyl)amino]acetic acid Chemical compound OC(=O)CN(CC(O)=O)CC(O)CN(CC(O)=O)CC(O)=O WYMDDFRYORANCC-UHFFFAOYSA-N 0.000 description 8
- 102100034544 Acyl-CoA 6-desaturase Human genes 0.000 description 8
- 108010037138 Linoleoyl-CoA Desaturase Proteins 0.000 description 8
- 229940100389 Sulfonylurea Drugs 0.000 description 8
- 108091023045 Untranslated Region Proteins 0.000 description 8
- 150000001720 carbohydrates Chemical class 0.000 description 8
- 235000014633 carbohydrates Nutrition 0.000 description 8
- 230000007423 decrease Effects 0.000 description 8
- 238000006731 degradation reaction Methods 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 230000036541 health Effects 0.000 description 8
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 8
- 230000003993 interaction Effects 0.000 description 8
- 230000007246 mechanism Effects 0.000 description 8
- 230000007935 neutral effect Effects 0.000 description 8
- 230000035764 nutrition Effects 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 210000005253 yeast cell Anatomy 0.000 description 8
- 101000693832 Arabidopsis thaliana Peroxisome biogenesis protein 2 Proteins 0.000 description 7
- 108010074051 C-Reactive Protein Proteins 0.000 description 7
- 102100032752 C-reactive protein Human genes 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 7
- 238000008214 LDL Cholesterol Methods 0.000 description 7
- 101100532752 Yarrowia lipolytica (strain CLIB 122 / E 150) SCP2 gene Proteins 0.000 description 7
- 244000144974 aquaculture Species 0.000 description 7
- 238000009360 aquaculture Methods 0.000 description 7
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 7
- 108020001507 fusion proteins Proteins 0.000 description 7
- 102000037865 fusion proteins Human genes 0.000 description 7
- 239000008103 glucose Substances 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 7
- 230000037353 metabolic pathway Effects 0.000 description 7
- 101150040807 pex14 gene Proteins 0.000 description 7
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 7
- 229940035893 uracil Drugs 0.000 description 7
- AVKOENOBFIYBSA-WMPRHZDHSA-N (4Z,7Z,10Z,13Z,16Z)-docosa-4,7,10,13,16-pentaenoic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O AVKOENOBFIYBSA-WMPRHZDHSA-N 0.000 description 6
- UHPMCKVQTMMPCG-UHFFFAOYSA-N 5,8-dihydroxy-2-methoxy-6-methyl-7-(2-oxopropyl)naphthalene-1,4-dione Chemical compound CC1=C(CC(C)=O)C(O)=C2C(=O)C(OC)=CC(=O)C2=C1O UHPMCKVQTMMPCG-UHFFFAOYSA-N 0.000 description 6
- 102000057234 Acyl transferases Human genes 0.000 description 6
- 229920001817 Agar Polymers 0.000 description 6
- 101000579348 Arabidopsis thaliana Peroxisomal membrane protein 13 Proteins 0.000 description 6
- 101000600176 Arabidopsis thaliana Peroxisomal membrane protein PEX14 Proteins 0.000 description 6
- 101000987688 Arabidopsis thaliana Peroxisome biogenesis protein 5 Proteins 0.000 description 6
- 102000053602 DNA Human genes 0.000 description 6
- 241000233866 Fungi Species 0.000 description 6
- 241000223218 Fusarium Species 0.000 description 6
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 6
- 241000907999 Mortierella alpina Species 0.000 description 6
- 101150056463 PEX5 gene Proteins 0.000 description 6
- 108010025366 Peroxins Proteins 0.000 description 6
- 102000013772 Peroxins Human genes 0.000 description 6
- 108010077056 Peroxisomal Targeting Signal 2 Receptor Proteins 0.000 description 6
- 102000009913 Peroxisomal Targeting Signal 2 Receptor Human genes 0.000 description 6
- 239000008272 agar Substances 0.000 description 6
- 230000000295 complement effect Effects 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 235000013365 dairy product Nutrition 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 239000003623 enhancer Substances 0.000 description 6
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 6
- 238000002744 homologous recombination Methods 0.000 description 6
- 230000006801 homologous recombination Effects 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 229910052500 inorganic mineral Inorganic materials 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 230000004060 metabolic process Effects 0.000 description 6
- 239000011707 mineral Substances 0.000 description 6
- 235000010755 mineral Nutrition 0.000 description 6
- 235000015097 nutrients Nutrition 0.000 description 6
- 210000003463 organelle Anatomy 0.000 description 6
- 230000003647 oxidation Effects 0.000 description 6
- SECPZKHBENQXJG-FPLPWBNLSA-N palmitoleic acid Chemical compound CCCCCC\C=C/CCCCCCCC(O)=O SECPZKHBENQXJG-FPLPWBNLSA-N 0.000 description 6
- 239000002243 precursor Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 150000003626 triacylglycerols Chemical class 0.000 description 6
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 6
- 101710103719 Acetolactate synthase large subunit Proteins 0.000 description 5
- 101710182467 Acetolactate synthase large subunit IlvB1 Proteins 0.000 description 5
- 101710171176 Acetolactate synthase large subunit IlvG Proteins 0.000 description 5
- 101710176702 Acetolactate synthase small subunit Proteins 0.000 description 5
- 101710147947 Acetolactate synthase small subunit 1, chloroplastic Proteins 0.000 description 5
- 101710095712 Acetolactate synthase, mitochondrial Proteins 0.000 description 5
- 241000024188 Andala Species 0.000 description 5
- 101100289888 Caenorhabditis elegans lys-5 gene Proteins 0.000 description 5
- 241000195493 Cryptophyta Species 0.000 description 5
- 102100036869 Diacylglycerol O-acyltransferase 1 Human genes 0.000 description 5
- 241000206602 Eukaryota Species 0.000 description 5
- UXDDRFCJKNROTO-UHFFFAOYSA-N Glycerol 1,2-diacetate Chemical compound CC(=O)OCC(CO)OC(C)=O UXDDRFCJKNROTO-UHFFFAOYSA-N 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 5
- 108090001060 Lipase Proteins 0.000 description 5
- 101710196435 Probable acetolactate synthase large subunit Proteins 0.000 description 5
- 101710181764 Probable acetolactate synthase small subunit Proteins 0.000 description 5
- 101710104000 Putative acetolactate synthase small subunit Proteins 0.000 description 5
- 241000918585 Pythium aphanidermatum Species 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000001851 biosynthetic effect Effects 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 238000012512 characterization method Methods 0.000 description 5
- 208000029078 coronary artery disease Diseases 0.000 description 5
- 235000021323 fish oil Nutrition 0.000 description 5
- 235000021588 free fatty acids Nutrition 0.000 description 5
- 230000002068 genetic effect Effects 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 5
- 235000013622 meat product Nutrition 0.000 description 5
- 238000010369 molecular cloning Methods 0.000 description 5
- 230000008488 polyadenylation Effects 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 238000012552 review Methods 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 150000004671 saturated fatty acids Chemical class 0.000 description 5
- 239000011782 vitamin Substances 0.000 description 5
- 235000013343 vitamin Nutrition 0.000 description 5
- 229930003231 vitamin Natural products 0.000 description 5
- 229940088594 vitamin Drugs 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 102100027328 2-hydroxyacyl-CoA lyase 2 Human genes 0.000 description 4
- 108020005544 Antisense RNA Proteins 0.000 description 4
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 4
- RZZPDXZPRHQOCG-OJAKKHQRSA-M CDP-choline(1-) Chemical compound O[C@@H]1[C@H](O)[C@@H](COP([O-])(=O)OP([O-])(=O)OCC[N+](C)(C)C)O[C@H]1N1C(=O)N=C(N)C=C1 RZZPDXZPRHQOCG-OJAKKHQRSA-M 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 4
- 208000011231 Crohn disease Diseases 0.000 description 4
- 102000036181 Fatty Acid Elongases Human genes 0.000 description 4
- 108010058732 Fatty Acid Elongases Proteins 0.000 description 4
- 241000233732 Fusarium verticillioides Species 0.000 description 4
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 101000927974 Homo sapiens Diacylglycerol O-acyltransferase 1 Proteins 0.000 description 4
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 4
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 4
- 239000004472 Lysine Substances 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- 108010055012 Orotidine-5'-phosphate decarboxylase Proteins 0.000 description 4
- 241000934740 Peridinium sp. Species 0.000 description 4
- 241000370518 Phytophthora ramorum Species 0.000 description 4
- 101000912235 Rebecca salina Acyl-lipid (7-3)-desaturase Proteins 0.000 description 4
- 101000877236 Siganus canaliculatus Acyl-CoA Delta-4 desaturase Proteins 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- 108010073771 Soybean Proteins Proteins 0.000 description 4
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 4
- 102000045404 acyltransferase activity proteins Human genes 0.000 description 4
- 108700014220 acyltransferase activity proteins Proteins 0.000 description 4
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 4
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 239000006227 byproduct Substances 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 239000003184 complementary RNA Substances 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 235000018417 cysteine Nutrition 0.000 description 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 4
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 4
- 235000013376 functional food Nutrition 0.000 description 4
- 235000013402 health food Nutrition 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 208000027866 inflammatory disease Diseases 0.000 description 4
- 230000000977 initiatory effect Effects 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 235000020778 linoleic acid Nutrition 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 235000020667 long-chain omega-3 fatty acid Nutrition 0.000 description 4
- 230000002503 metabolic effect Effects 0.000 description 4
- 230000002018 overexpression Effects 0.000 description 4
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 4
- 150000003904 phospholipids Chemical class 0.000 description 4
- 150000003180 prostaglandins Chemical class 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 235000003441 saturated fatty acids Nutrition 0.000 description 4
- 238000002741 site-directed mutagenesis Methods 0.000 description 4
- 235000011888 snacks Nutrition 0.000 description 4
- 229940001941 soy protein Drugs 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 230000002103 transcriptional effect Effects 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 238000000844 transformation Methods 0.000 description 4
- 230000005945 translocation Effects 0.000 description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 4
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 4
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 4
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 3
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 description 3
- 108010000700 Acetolactate synthase Proteins 0.000 description 3
- 101150040074 Aco2 gene Proteins 0.000 description 3
- 229920002498 Beta-glucan Polymers 0.000 description 3
- 229920002101 Chitin Polymers 0.000 description 3
- 206010009900 Colitis ulcerative Diseases 0.000 description 3
- 102100025287 Cytochrome b Human genes 0.000 description 3
- 108010075028 Cytochromes b Proteins 0.000 description 3
- 235000021294 Docosapentaenoic acid Nutrition 0.000 description 3
- 244000025670 Eleusine indica Species 0.000 description 3
- 101150095274 FBA1 gene Proteins 0.000 description 3
- 241000221778 Fusarium fujikuroi Species 0.000 description 3
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 108091092195 Intron Proteins 0.000 description 3
- 108010044467 Isoenzymes Proteins 0.000 description 3
- 102000004882 Lipase Human genes 0.000 description 3
- 239000004367 Lipase Substances 0.000 description 3
- 229920000057 Mannan Polymers 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 235000021360 Myristic acid Nutrition 0.000 description 3
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 3
- 108091092724 Noncoding DNA Proteins 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- 108700026244 Open Reading Frames Proteins 0.000 description 3
- 208000001132 Osteoporosis Diseases 0.000 description 3
- 235000021314 Palmitic acid Nutrition 0.000 description 3
- 235000021319 Palmitoleic acid Nutrition 0.000 description 3
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 3
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 3
- 101710133727 Phospholipid:diacylglycerol acyltransferase Proteins 0.000 description 3
- 241000282849 Ruminantia Species 0.000 description 3
- 108010052160 Site-specific recombinase Proteins 0.000 description 3
- 102000001494 Sterol O-Acyltransferase Human genes 0.000 description 3
- 108010054082 Sterol O-acyltransferase Proteins 0.000 description 3
- 108700005078 Synthetic Genes Proteins 0.000 description 3
- 108010020764 Transposases Proteins 0.000 description 3
- 102000008579 Transposases Human genes 0.000 description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 description 3
- 241000490645 Yarrowia sp. Species 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 235000010419 agar Nutrition 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 208000022531 anorexia Diseases 0.000 description 3
- 230000000692 anti-sense effect Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 229940041514 candida albicans extract Drugs 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 230000002759 chromosomal effect Effects 0.000 description 3
- SECPZKHBENQXJG-UHFFFAOYSA-N cis-palmitoleic acid Natural products CCCCCCC=CCCCCCCCC(O)=O SECPZKHBENQXJG-UHFFFAOYSA-N 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 210000000172 cytosol Anatomy 0.000 description 3
- 206010061428 decreased appetite Diseases 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 150000001982 diacylglycerols Chemical class 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 235000001434 dietary modification Nutrition 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 230000002538 fungal effect Effects 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000007407 health benefit Effects 0.000 description 3
- 239000004009 herbicide Substances 0.000 description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 3
- 235000020256 human milk Nutrition 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 150000002617 leukotrienes Chemical class 0.000 description 3
- 235000019421 lipase Nutrition 0.000 description 3
- 230000037356 lipid metabolism Effects 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 201000008482 osteoarthritis Diseases 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 230000000858 peroxisomal effect Effects 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 3
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 3
- 244000144977 poultry Species 0.000 description 3
- 235000013594 poultry meat Nutrition 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 201000000980 schizophrenia Diseases 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 230000002194 synthesizing effect Effects 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- 239000012138 yeast extract Substances 0.000 description 3
- XSXIVVZCUAHUJO-AVQMFFATSA-N (11e,14e)-icosa-11,14-dienoic acid Chemical compound CCCCC\C=C\C\C=C\CCCCCCCCCC(O)=O XSXIVVZCUAHUJO-AVQMFFATSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- KPULXFNPTWGJQH-UHFFFAOYSA-N 3-hydroxy-4-oxo-4-propan-2-yloxybutanoic acid Chemical compound CC(C)OC(=O)C(O)CC(O)=O KPULXFNPTWGJQH-UHFFFAOYSA-N 0.000 description 2
- LODRRYMGPWQCTR-UHFFFAOYSA-N 5-fluoro-2,4-dioxo-1h-pyrimidine-6-carboxylic acid;hydrate Chemical compound O.OC(=O)C=1NC(=O)NC(=O)C=1F LODRRYMGPWQCTR-UHFFFAOYSA-N 0.000 description 2
- 101150093595 ACO1 gene Proteins 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- 241000272517 Anseriformes Species 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 235000007319 Avena orientalis Nutrition 0.000 description 2
- 244000075850 Avena orientalis Species 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 2
- 108090000489 Carboxy-Lyases Proteins 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- SBJKKFFYIZUCET-JLAZNSOCSA-N Dehydro-L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-JLAZNSOCSA-N 0.000 description 2
- 101710088194 Dehydrogenase Proteins 0.000 description 2
- 235000021298 Dihomo-γ-linolenic acid Nutrition 0.000 description 2
- 235000021297 Eicosadienoic acid Nutrition 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 229920000064 Ethyl eicosapentaenoic acid Polymers 0.000 description 2
- 102000009114 Fatty acid desaturases Human genes 0.000 description 2
- 102000001390 Fructose-Bisphosphate Aldolase Human genes 0.000 description 2
- 108010068561 Fructose-Bisphosphate Aldolase Proteins 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 229930186217 Glycolipid Natural products 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 241000270322 Lepidosauria Species 0.000 description 2
- 208000019693 Lung disease Diseases 0.000 description 2
- 240000002129 Malva sylvestris Species 0.000 description 2
- 235000006770 Malva sylvestris Nutrition 0.000 description 2
- 208000001145 Metabolic Syndrome Diseases 0.000 description 2
- 102100037214 Orotidine 5'-phosphate decarboxylase Human genes 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 101150059359 POX2 gene Proteins 0.000 description 2
- 241000286209 Phasianidae Species 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 241000223252 Rhodotorula Species 0.000 description 2
- 101100106445 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) YLR050C gene Proteins 0.000 description 2
- 241000209056 Secale Species 0.000 description 2
- 235000007238 Secale cereale Nutrition 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 244000062793 Sorghum vulgare Species 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 108700009124 Transcription Initiation Site Proteins 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 108700019146 Transgenes Proteins 0.000 description 2
- 235000021307 Triticum Nutrition 0.000 description 2
- 244000098338 Triticum aestivum Species 0.000 description 2
- KYOBSHFOBAOFBF-UHFFFAOYSA-N UMP Natural products OC1C(O)C(COP(O)(O)=O)OC1N1C(=O)NC(=O)C=C1C(O)=O KYOBSHFOBAOFBF-UHFFFAOYSA-N 0.000 description 2
- 101150050575 URA3 gene Proteins 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 238000002869 basic local alignment search tool Methods 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical class OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 235000012970 cakes Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 230000007211 cardiovascular event Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 235000013330 chicken meat Nutrition 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 239000013599 cloning vector Substances 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 229940090949 docosahexaenoic acid Drugs 0.000 description 2
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 230000032050 esterification Effects 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- SSQPWTVBQMWLSZ-AAQCHOMXSA-N ethyl (5Z,8Z,11Z,14Z,17Z)-icosapentaenoate Chemical compound CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC SSQPWTVBQMWLSZ-AAQCHOMXSA-N 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000004133 fatty acid degradation Effects 0.000 description 2
- 150000002190 fatty acyls Chemical group 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 description 2
- 229960002733 gamolenic acid Drugs 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000006481 glucose medium Substances 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 235000011868 grain product Nutrition 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 150000003278 haem Chemical class 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 230000002363 herbicidal effect Effects 0.000 description 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 2
- VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 229960004488 linolenic acid Drugs 0.000 description 2
- 238000009630 liquid culture Methods 0.000 description 2
- 102000004311 liver X receptors Human genes 0.000 description 2
- 108090000865 liver X receptors Proteins 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 150000004668 long chain fatty acids Chemical class 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 235000013310 margarine Nutrition 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 150000002759 monoacylglycerols Chemical class 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- UTOPWMOLSKOLTQ-UHFFFAOYSA-N octacosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCC(O)=O UTOPWMOLSKOLTQ-UHFFFAOYSA-N 0.000 description 2
- 108010033653 omega-3 fatty acid desaturase Proteins 0.000 description 2
- KYOBSHFOBAOFBF-XVFCMESISA-N orotidine 5'-phosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1C(O)=O KYOBSHFOBAOFBF-XVFCMESISA-N 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 235000019629 palatability Nutrition 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 235000015927 pasta Nutrition 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 235000013324 preserved food Nutrition 0.000 description 2
- 235000020991 processed meat Nutrition 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 208000020016 psychiatric disease Diseases 0.000 description 2
- 235000020989 red meat Nutrition 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- AOPOCGPBAIARAV-OTBJXLELSA-N resolvin E1 Chemical compound CC[C@@H](O)\C=C\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O AOPOCGPBAIARAV-OTBJXLELSA-N 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 102000002774 saccharopine dehydrogenase Human genes 0.000 description 2
- 108020000318 saccharopine dehydrogenase Proteins 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000010187 selection method Methods 0.000 description 2
- 150000004666 short chain fatty acids Chemical class 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 150000003463 sulfur Chemical class 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 2
- 229940045145 uridine Drugs 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- GWHCXVQVJPWHRF-KTKRTIGZSA-N (15Z)-tetracosenoic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCCCC(O)=O GWHCXVQVJPWHRF-KTKRTIGZSA-N 0.000 description 1
- FPRKGXIOSIUDSE-SYACGTDESA-N (2z,4z,6z,8z)-docosa-2,4,6,8-tetraenoic acid Chemical compound CCCCCCCCCCCCC\C=C/C=C\C=C/C=C\C(O)=O FPRKGXIOSIUDSE-SYACGTDESA-N 0.000 description 1
- JDKIKEYFSJUYJZ-OUJQXAOTSA-N (5Z,11Z,14Z,17Z)-icosatetraenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCC\C=C/CCCC(O)=O JDKIKEYFSJUYJZ-OUJQXAOTSA-N 0.000 description 1
- YUFFSWGQGVEMMI-UHFFFAOYSA-N (7Z,10Z,13Z,16Z,19Z)-7,10,13,16,19-docosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCCCC(O)=O YUFFSWGQGVEMMI-UHFFFAOYSA-N 0.000 description 1
- CUXYLFPMQMFGPL-UHFFFAOYSA-N (9Z,11E,13E)-9,11,13-Octadecatrienoic acid Natural products CCCCC=CC=CC=CCCCCCCCC(O)=O CUXYLFPMQMFGPL-UHFFFAOYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 1
- OUKQYSCCWVCDKU-UHFFFAOYSA-N 1-[(3,4-diethoxyphenyl)methyl]-6,7-diethoxy-3,4-dihydroisoquinolin-2-ium;2-(1,3-dimethyl-2,6-dioxopurin-7-yl)acetate Chemical compound O=C1N(C)C(=O)N(C)C2=C1N(CC(O)=O)C=N2.C1=C(OCC)C(OCC)=CC=C1CC1=NCCC2=CC(OCC)=C(OCC)C=C12 OUKQYSCCWVCDKU-UHFFFAOYSA-N 0.000 description 1
- 101710124165 1-acyl-sn-glycerol-3-phosphate acyltransferase Proteins 0.000 description 1
- 102100031251 1-acylglycerol-3-phosphate O-acyltransferase PNPLA3 Human genes 0.000 description 1
- WRGQSWVCFNIUNZ-GDCKJWNLSA-N 1-oleoyl-sn-glycerol 3-phosphate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)COP(O)(O)=O WRGQSWVCFNIUNZ-GDCKJWNLSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- KAWIOCMUARENDQ-UHFFFAOYSA-N 2-(4-chlorophenyl)sulfanyl-n-(4-pyridin-2-yl-1,3-thiazol-2-yl)acetamide Chemical compound C1=CC(Cl)=CC=C1SCC(=O)NC1=NC(C=2N=CC=CC=2)=CS1 KAWIOCMUARENDQ-UHFFFAOYSA-N 0.000 description 1
- 108010054662 2-acylglycerophosphate acyltransferase Proteins 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- CAAMSDWKXXPUJR-UHFFFAOYSA-N 3,5-dihydro-4H-imidazol-4-one Chemical compound O=C1CNC=N1 CAAMSDWKXXPUJR-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 101150014984 ACO gene Proteins 0.000 description 1
- 230000002407 ATP formation Effects 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 108010003902 Acetyl-CoA C-acyltransferase Proteins 0.000 description 1
- 102000004672 Acetyl-CoA C-acyltransferase Human genes 0.000 description 1
- 240000000073 Achillea millefolium Species 0.000 description 1
- 235000007754 Achillea millefolium Nutrition 0.000 description 1
- 102100027840 Acyl-CoA wax alcohol acyltransferase 1 Human genes 0.000 description 1
- 102100022089 Acyl-[acyl-carrier-protein] hydrolase Human genes 0.000 description 1
- 241000590031 Alteromonas Species 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 102100039338 Aminomethyltransferase, mitochondrial Human genes 0.000 description 1
- 108050001492 Ammonium transporters Proteins 0.000 description 1
- 241000238426 Anostraca Species 0.000 description 1
- 108700012837 Arabidopsis Pex16 Proteins 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000206761 Bacillariophyta Species 0.000 description 1
- 108010023063 Bacto-peptone Proteins 0.000 description 1
- 235000021357 Behenic acid Nutrition 0.000 description 1
- 239000005711 Benzoic acid Chemical class 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- 108010029692 Bisphosphoglycerate mutase Proteins 0.000 description 1
- 240000002791 Brassica napus Species 0.000 description 1
- 241000273930 Brevoortia tyrannus Species 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 101150098791 CPT1 gene Proteins 0.000 description 1
- 235000017399 Caesalpinia tinctoria Nutrition 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241001086914 Candida deformans Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 102100035882 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 241000238366 Cephalopoda Species 0.000 description 1
- 240000008886 Ceratonia siliqua Species 0.000 description 1
- 235000013912 Ceratonia siliqua Nutrition 0.000 description 1
- 240000006162 Chenopodium quinoa Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 241000555825 Clupeidae Species 0.000 description 1
- 241001454694 Clupeiformes Species 0.000 description 1
- RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 description 1
- 241000254173 Coleoptera Species 0.000 description 1
- 108010051219 Cre recombinase Proteins 0.000 description 1
- 241001527609 Cryptococcus Species 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 102100026908 D-amino-acid oxidase Human genes 0.000 description 1
- 108010003989 D-amino-acid oxidase Proteins 0.000 description 1
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
- 101100009781 Danio rerio dmbx1a gene Proteins 0.000 description 1
- 108050004099 Diacylglycerol O-acyltransferase 1 Proteins 0.000 description 1
- 108010006731 Dimethylallyltranstransferase Proteins 0.000 description 1
- 102000005454 Dimethylallyltranstransferase Human genes 0.000 description 1
- 235000021292 Docosatetraenoic acid Nutrition 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 239000004258 Ethoxyquin Substances 0.000 description 1
- 108091029865 Exogenous DNA Proteins 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 101710158368 Extracellular lipase Proteins 0.000 description 1
- 101710089384 Extracellular protease Proteins 0.000 description 1
- 101800002290 Extracellular triacylglycerol lipase Proteins 0.000 description 1
- 102000000429 Factor XII Human genes 0.000 description 1
- 108010080865 Factor XII Proteins 0.000 description 1
- 108010039731 Fatty Acid Synthases Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- OPGOLNDOMSBSCW-CLNHMMGSSA-N Fursultiamine hydrochloride Chemical compound Cl.C1CCOC1CSSC(\CCO)=C(/C)N(C=O)CC1=CN=C(C)N=C1N OPGOLNDOMSBSCW-CLNHMMGSSA-N 0.000 description 1
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 1
- 108010018837 Glycerol-3-Phosphate O-Acyltransferase Proteins 0.000 description 1
- 102000002754 Glycerol-3-Phosphate O-Acyltransferase Human genes 0.000 description 1
- 108030000884 Glycerol-3-phosphate 1-O-acyltransferases Proteins 0.000 description 1
- 101710091951 Glycerol-3-phosphate acyltransferase Proteins 0.000 description 1
- 102100024017 Glycerol-3-phosphate acyltransferase 3 Human genes 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 101000698136 Homo sapiens Acyl-CoA wax alcohol acyltransferase 1 Proteins 0.000 description 1
- 101100084403 Homo sapiens PRODH gene Proteins 0.000 description 1
- 101001130226 Homo sapiens Phosphatidylcholine-sterol acyltransferase Proteins 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 241001501885 Isochrysis Species 0.000 description 1
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical group CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 1
- 241000235649 Kluyveromyces Species 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 235000021353 Lignoceric acid Nutrition 0.000 description 1
- CQXMAMUUWHYSIY-UHFFFAOYSA-N Lignoceric acid Natural products CCCCCCCCCCCCCCCCCCCCCCCC(=O)OCCC1=CC=C(O)C=C1 CQXMAMUUWHYSIY-UHFFFAOYSA-N 0.000 description 1
- 101710084369 Lipase 4 Proteins 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 241001149698 Lipomyces Species 0.000 description 1
- 101710097496 Lysophospholipid acyltransferase Proteins 0.000 description 1
- 102100038805 Lysophospholipid acyltransferase 2 Human genes 0.000 description 1
- 101710163746 Lysophospholipid acyltransferase 2 Proteins 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 101710159527 Maturation protein A Proteins 0.000 description 1
- 101710091157 Maturation protein A2 Proteins 0.000 description 1
- 108091027974 Mature messenger RNA Proteins 0.000 description 1
- 240000004658 Medicago sativa Species 0.000 description 1
- 235000017587 Medicago sativa ssp. sativa Nutrition 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241001219224 Mortierella elongata Species 0.000 description 1
- 241000048020 Mortierella exigua Species 0.000 description 1
- 241000133355 Mortierella hygrophila Species 0.000 description 1
- 101000913652 Mus musculus Fibronectin type III domain-containing protein 5 Proteins 0.000 description 1
- XJXROGWVRIJYMO-SJDLZYGOSA-N Nervonic acid Natural products O=C(O)[C@@H](/C=C/CCCCCCCC)CCCCCCCCCCCC XJXROGWVRIJYMO-SJDLZYGOSA-N 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 241000486043 Nitzschia sp. (in: Bacillariophyta) Species 0.000 description 1
- 241000272458 Numididae Species 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 241000233654 Oomycetes Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 101150105372 POX1 gene Proteins 0.000 description 1
- 101150114097 POX3 gene Proteins 0.000 description 1
- 101150053659 POX4 gene Proteins 0.000 description 1
- 101150004239 POX5 gene Proteins 0.000 description 1
- 102000023984 PPAR alpha Human genes 0.000 description 1
- 102100033359 Pancreatic triacylglycerol lipase Human genes 0.000 description 1
- 241000287127 Passeridae Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000002508 Peptide Elongation Factors Human genes 0.000 description 1
- 108010068204 Peptide Elongation Factors Proteins 0.000 description 1
- 108010085186 Peroxisomal Targeting Signals Proteins 0.000 description 1
- 101710195300 Peroxisomal catalase Proteins 0.000 description 1
- 101710196890 Peroxisome biogenesis factor 10 Proteins 0.000 description 1
- 102100030554 Peroxisome biogenesis factor 10 Human genes 0.000 description 1
- 108010002747 Pfu DNA polymerase Proteins 0.000 description 1
- 102000001107 Phosphatidate Phosphatase Human genes 0.000 description 1
- 108010069394 Phosphatidate Phosphatase Proteins 0.000 description 1
- 102100031538 Phosphatidylcholine-sterol acyltransferase Human genes 0.000 description 1
- 102000011025 Phosphoglycerate Mutase Human genes 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- 241000233622 Phytophthora infestans Species 0.000 description 1
- 241000948155 Phytophthora sojae Species 0.000 description 1
- 241000209504 Poaceae Species 0.000 description 1
- 201000009916 Postpartum depression Diseases 0.000 description 1
- 101710172946 Probable 1-acyl-sn-glycerol-3-phosphate acyltransferase Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 102100028772 Proline dehydrogenase 1, mitochondrial Human genes 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000233639 Pythium Species 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 101150091684 SPS4 gene Proteins 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 101100313649 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) POT1 gene Proteins 0.000 description 1
- 241000277331 Salmonidae Species 0.000 description 1
- 241000235346 Schizosaccharomyces Species 0.000 description 1
- 241000863430 Shewanella Species 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 206010040829 Skin discolouration Diseases 0.000 description 1
- 235000011684 Sorghum saccharatum Nutrition 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 102000009822 Sterol Regulatory Element Binding Proteins Human genes 0.000 description 1
- 108010020396 Sterol Regulatory Element Binding Proteins Proteins 0.000 description 1
- 241001466451 Stramenopiles Species 0.000 description 1
- 241001228709 Suruga Species 0.000 description 1
- 241000388430 Tara Species 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 101710128940 Triacylglycerol lipase Proteins 0.000 description 1
- 241000223230 Trichosporon Species 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 108010092464 Urate Oxidase Proteins 0.000 description 1
- 108010069201 VLDL Cholesterol Proteins 0.000 description 1
- 235000021322 Vaccenic acid Nutrition 0.000 description 1
- UWHZIFQPPBDJPM-FPLPWBNLSA-M Vaccenic acid Natural products CCCCCC\C=C/CCCCCCCCCC([O-])=O UWHZIFQPPBDJPM-FPLPWBNLSA-M 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 101100161758 Yarrowia lipolytica (strain CLIB 122 / E 150) POX3 gene Proteins 0.000 description 1
- 241000798866 Yarrowia lipolytica CLIB122 Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 101100194320 Zea mays PER1 gene Proteins 0.000 description 1
- 101100029251 Zea mays PER2 gene Proteins 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 241000746966 Zizania Species 0.000 description 1
- 235000002636 Zizania aquatica Nutrition 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 201000010390 abdominal obesity-metabolic syndrome 1 Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- AHANXAKGNAKFSK-PDBXOOCHSA-N all-cis-icosa-11,14,17-trienoic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCCCC(O)=O AHANXAKGNAKFSK-PDBXOOCHSA-N 0.000 description 1
- CUXYLFPMQMFGPL-SUTYWZMXSA-N all-trans-octadeca-9,11,13-trienoic acid Chemical compound CCCC\C=C\C=C\C=C\CCCCCCCC(O)=O CUXYLFPMQMFGPL-SUTYWZMXSA-N 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 125000000266 alpha-aminoacyl group Chemical group 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 235000019513 anchovy Nutrition 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003529 anticholesteremic agent Substances 0.000 description 1
- 229940127226 anticholesterol agent Drugs 0.000 description 1
- 229940053200 antiepileptics fatty acid derivative Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 235000013527 bean curd Nutrition 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 229940116226 behenic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 231100000693 bioaccumulation Toxicity 0.000 description 1
- 239000012867 bioactive agent Substances 0.000 description 1
- 230000008238 biochemical pathway Effects 0.000 description 1
- 230000008436 biogenesis Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000007321 biological mechanism Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 150000005693 branched-chain amino acids Chemical class 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000012813 breadcrumbs Nutrition 0.000 description 1
- 235000015496 breakfast cereal Nutrition 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000005961 cardioprotection Effects 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000030570 cellular localization Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000002975 chemoattractant Substances 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- NSWAMPCUPHPTTC-UHFFFAOYSA-N chlorimuron-ethyl Chemical group CCOC(=O)C1=CC=CC=C1S(=O)(=O)NC(=O)NC1=NC(Cl)=CC(OC)=N1 NSWAMPCUPHPTTC-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- GWHCXVQVJPWHRF-UHFFFAOYSA-N cis-tetracosenoic acid Natural products CCCCCCCCC=CCCCCCCCCCCCCCC(O)=O GWHCXVQVJPWHRF-UHFFFAOYSA-N 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 1
- 239000005516 coenzyme A Substances 0.000 description 1
- 229940093530 coenzyme a Drugs 0.000 description 1
- 235000016213 coffee Nutrition 0.000 description 1
- 235000013353 coffee beverage Nutrition 0.000 description 1
- 235000014156 coffee whiteners Nutrition 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 239000008162 cooking oil Substances 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- IERHLVCPSMICTF-UHFFFAOYSA-N cytidine monophosphate Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(COP(O)(O)=O)O1 IERHLVCPSMICTF-UHFFFAOYSA-N 0.000 description 1
- IERHLVCPSMICTF-ZAKLUEHWSA-N cytidine-5'-monophosphate Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](COP(O)(O)=O)O1 IERHLVCPSMICTF-ZAKLUEHWSA-N 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 1
- 235000011850 desserts Nutrition 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- XIVFQYWMMJWUCD-UHFFFAOYSA-N dihydrophaseic acid Natural products C1C(O)CC2(C)OCC1(C)C2(O)C=CC(C)=CC(O)=O XIVFQYWMMJWUCD-UHFFFAOYSA-N 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 235000012489 doughnuts Nutrition 0.000 description 1
- 238000011143 downstream manufacturing Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000001214 effect on cellular process Effects 0.000 description 1
- 150000002066 eicosanoids Chemical class 0.000 description 1
- IQLUYYHUNSSHIY-HZUMYPAESA-N eicosatetraenoic acid Chemical compound CCCCCCCCCCC\C=C\C=C\C=C\C=C\C(O)=O IQLUYYHUNSSHIY-HZUMYPAESA-N 0.000 description 1
- PRHHYVQTPBEDFE-UHFFFAOYSA-N eicosatrienoic acid Natural products CCCCCC=CCC=CCCCCC=CCCCC(O)=O PRHHYVQTPBEDFE-UHFFFAOYSA-N 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 101150019586 elo-3 gene Proteins 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000004146 energy storage Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical class C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 235000019285 ethoxyquin Nutrition 0.000 description 1
- DECIPOUIJURFOJ-UHFFFAOYSA-N ethoxyquin Chemical compound N1C(C)(C)C=C(C)C2=CC(OCC)=CC=C21 DECIPOUIJURFOJ-UHFFFAOYSA-N 0.000 description 1
- 229940093500 ethoxyquin Drugs 0.000 description 1
- FARYTWBWLZAXNK-WAYWQWQTSA-N ethyl (z)-3-(methylamino)but-2-enoate Chemical compound CCOC(=O)\C=C(\C)NC FARYTWBWLZAXNK-WAYWQWQTSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 101150017244 exp-1 gene Proteins 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000004129 fatty acid metabolism Effects 0.000 description 1
- 230000004136 fatty acid synthesis Effects 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 235000021001 fermented dairy product Nutrition 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000013505 freshwater Substances 0.000 description 1
- 235000013611 frozen food Nutrition 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007897 gelcap Substances 0.000 description 1
- 108091008053 gene clusters Proteins 0.000 description 1
- 238000010359 gene isolation Methods 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000021552 granulated sugar Nutrition 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 235000019692 hotdogs Nutrition 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 108010002685 hygromycin-B kinase Proteins 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000012405 in silico analysis Methods 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 1
- 235000021129 infant diet Nutrition 0.000 description 1
- 235000021125 infant nutrition Nutrition 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 235000015094 jam Nutrition 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000006372 lipid accumulation Effects 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 235000014666 liquid concentrate Nutrition 0.000 description 1
- XIXADJRWDQXREU-UHFFFAOYSA-M lithium acetate Chemical compound [Li+].CC([O-])=O XIXADJRWDQXREU-UHFFFAOYSA-M 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 235000010598 long-chain omega-6 fatty acid Nutrition 0.000 description 1
- 235000020978 long-chain polyunsaturated fatty acids Nutrition 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 208000011661 metabolic syndrome X Diseases 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 235000020124 milk-based beverage Nutrition 0.000 description 1
- 235000019713 millet Nutrition 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 235000021281 monounsaturated fatty acids Nutrition 0.000 description 1
- 230000003188 neurobehavioral effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 1
- 230000001937 non-anti-biotic effect Effects 0.000 description 1
- 239000000820 nonprescription drug Substances 0.000 description 1
- 235000021049 nutrient content Nutrition 0.000 description 1
- 235000021048 nutrient requirements Nutrition 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 229920002113 octoxynol Polymers 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 235000016236 parenteral nutrition Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 238000009372 pisciculture Methods 0.000 description 1
- 230000037039 plant physiology Effects 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 235000013613 poultry product Nutrition 0.000 description 1
- 235000008476 powdered milk Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000013630 prepared media Substances 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 235000012434 pretzels Nutrition 0.000 description 1
- 230000019525 primary metabolic process Effects 0.000 description 1
- 230000009862 primary prevention Effects 0.000 description 1
- 230000000135 prohibitive effect Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 235000011962 puddings Nutrition 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical class O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 235000020122 reconstituted milk Nutrition 0.000 description 1
- 230000014493 regulation of gene expression Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 235000019512 sardine Nutrition 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000013535 sea water Substances 0.000 description 1
- 230000009863 secondary prevention Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 235000021391 short chain fatty acids Nutrition 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 230000003584 silencer Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Chemical class 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000021262 sour milk Nutrition 0.000 description 1
- 235000013322 soy milk Nutrition 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 230000028070 sporulation Effects 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- JIWBIWFOSCKQMA-UHFFFAOYSA-N stearidonic acid Natural products CCC=CCC=CCC=CCC=CCCCCC(O)=O JIWBIWFOSCKQMA-UHFFFAOYSA-N 0.000 description 1
- 108010058363 sterol carrier proteins Proteins 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 235000021092 sugar substitutes Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 238000000194 supercritical-fluid extraction Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 150000003595 thromboxanes Chemical class 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- UWHZIFQPPBDJPM-BQYQJAHWSA-N trans-vaccenic acid Chemical compound CCCCCC\C=C\CCCCCCCCCC(O)=O UWHZIFQPPBDJPM-BQYQJAHWSA-N 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000017105 transposition Effects 0.000 description 1
- 150000005691 triesters Chemical class 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 229940005267 urate oxidase Drugs 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 150000004669 very long chain fatty acids Chemical class 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 235000020985 whole grains Nutrition 0.000 description 1
- 235000008939 whole milk Nutrition 0.000 description 1
- 239000012130 whole-cell lysate Substances 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
- C12P7/6409—Fatty acids
- C12P7/6427—Polyunsaturated fatty acids [PUFA], i.e. having two or more double bonds in their backbone
- C12P7/6432—Eicosapentaenoic acids [EPA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
- C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
- C12N9/0083—Miscellaneous (1.14.99)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1025—Acyltransferases (2.3)
- C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
- C12P7/6436—Fatty acid esters
- C12P7/6445—Glycerides
- C12P7/6458—Glycerides by transesterification, e.g. interesterification, ester interchange, alcoholysis or acidolysis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
- C12P7/6436—Fatty acid esters
- C12P7/6445—Glycerides
- C12P7/6472—Glycerides containing polyunsaturated fatty acid [PUFA] residues, i.e. having two or more double bonds in their backbone
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Plant Pathology (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97717407P | 2007-10-03 | 2007-10-03 | |
| US97717707P | 2007-10-03 | 2007-10-03 | |
| US60/977,174 | 2007-10-03 | ||
| US60/977,177 | 2007-10-03 | ||
| PCT/US2008/078642 WO2009046231A1 (en) | 2007-10-03 | 2008-10-03 | Optimized strains of yarrowia lipolytica for high eicosapentaenoic acid production |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011501661A JP2011501661A (ja) | 2011-01-13 |
| JP2011501661A5 JP2011501661A5 (enExample) | 2011-11-17 |
| JP5711968B2 true JP5711968B2 (ja) | 2015-05-07 |
Family
ID=40084411
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010528141A Expired - Fee Related JP5711968B2 (ja) | 2007-10-03 | 2008-10-03 | 高エイコサペンタエン酸を生成するためのヤロウィア・リポリティカ(YarrowiaLipolytica)の最適化株 |
Country Status (6)
| Country | Link |
|---|---|
| US (5) | US8323935B2 (enExample) |
| EP (1) | EP2195415A1 (enExample) |
| JP (1) | JP5711968B2 (enExample) |
| CN (1) | CN101970638B (enExample) |
| CA (1) | CA2701094A1 (enExample) |
| WO (1) | WO2009046231A1 (enExample) |
Families Citing this family (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8313911B2 (en) * | 2003-05-07 | 2012-11-20 | E I Du Pont De Nemours And Company | Production of polyunsaturated fatty acids in oleaginous yeasts |
| US8119860B2 (en) * | 2007-04-16 | 2012-02-21 | E. I. Du Pont De Nemours And Company | Delta-9 elongases and their use in making polyunsaturated fatty acids |
| US7943365B2 (en) * | 2007-05-03 | 2011-05-17 | E.I. Du Pont De Nemours And Company | Δ-5 desaturases and their use in making polyunsaturated fatty acids |
| JP2010528627A (ja) | 2007-06-01 | 2010-08-26 | ソラザイム、インク | 微生物による油の生産 |
| EP2324120B1 (en) | 2008-08-29 | 2016-01-27 | E. I. du Pont de Nemours and Company | Manipulation of snf1 protein kinase activity for altered oil content in oleaginous organisms |
| DK2324119T3 (en) * | 2008-09-19 | 2016-07-18 | Du Pont | Mutant DELTA5 Desaturases AND USE THEREOF FOR THE PRODUCTION OF polyunsaturated fatty acids |
| CA2744716C (en) | 2008-12-18 | 2017-05-23 | E.I. Du Pont De Nemours And Company | Reducing byproduction of malonates in a fermentation process |
| US8207363B2 (en) * | 2009-03-19 | 2012-06-26 | Martek Biosciences Corporation | Thraustochytrids, fatty acid compositions, and methods of making and uses thereof |
| CN102803289B (zh) * | 2009-06-16 | 2015-07-22 | 纳幕尔杜邦公司 | 用于高水平生产二十碳五烯酸的改善的优化的解脂耶氏酵母菌株 |
| US8399226B2 (en) * | 2009-06-16 | 2013-03-19 | E I Du Pont De Nemours And Company | High eicosapentaenoic acid oils from improved optimized strains of Yarrowia lipolytica |
| WO2010147907A1 (en) | 2009-06-16 | 2010-12-23 | E. I. Du Pont De Nemours And Company | High eicosapentaenoic acid oils from improved optimized strains of yarrowia lipolytica |
| BRPI1009690A2 (pt) * | 2009-06-16 | 2015-08-25 | Du Pont | "célula hospedeira microbiana oleaginosa, óleo, método de elaboração de um óleo, método de aumento da eficiência de conversão de alongamento de c18 para c20 em uma célula hospedeira recombinante microbiana oleaginosa e método de aumento da eficiência de conversão de dessaturação (delta) 4 em uma célula hospedeira recombinante microbiana oleaginosa produtora de ácidos graxos póli-insaturados de cadeia longa" |
| WO2011087981A2 (en) | 2010-01-15 | 2011-07-21 | E. I. Du Pont De Nemours And Company | Clinical benefits of eicosapentaenoic acid in humans |
| CA2993690C (en) | 2010-01-19 | 2022-03-22 | Dsm Ip Assets B.V. | Eicosapentaenoic acid-producing microorganisms, fatty acid compositions, and methods of making and uses thereof |
| CN103282474A (zh) | 2010-04-22 | 2013-09-04 | 纳幕尔杜邦公司 | 从微生物生物质中获得包含多不饱和脂肪酸的组合物的方法 |
| SG10201504197SA (en) * | 2010-05-28 | 2015-06-29 | Solazyme Inc | Food Compositions Comprising Tailored Oils |
| JP5678180B2 (ja) | 2010-06-09 | 2015-02-25 | フォトンズ コーポレーション リミテッド | 高度精製に適した、エイコサペンタエン酸を含む組成物 |
| WO2012021686A1 (en) | 2010-08-11 | 2012-02-16 | E. I. Du Pont De Nemours And Company | Improved aquaculture meat products |
| US20120040076A1 (en) | 2010-08-11 | 2012-02-16 | E. I. Du Pont De Nemours And Company | Aquaculture feed compositions |
| TW201207116A (en) | 2010-08-13 | 2012-02-16 | Univ Fu Jen Catholic | A method for producing oil by Cystofilobasidium spp. |
| WO2012027676A1 (en) | 2010-08-26 | 2012-03-01 | E. I. Du Pont De Nemours And Company | Mutant delta-9 elongases and their use in making polyunsaturated fatty acids |
| US8703473B2 (en) | 2010-08-26 | 2014-04-22 | E I Du Pont De Nemours And Company | Recombinant microbial host cells for high eicosapentaenoic acid production |
| AU2011293189B2 (en) * | 2010-08-26 | 2017-02-16 | E. I. Du Pont De Nemours And Company | Mutant HPGG motif and HDASH motif delta-5 desaturases and their use in making polyunsaturated fatty acids |
| EP3521408B1 (en) | 2010-11-03 | 2021-12-22 | Corbion Biotech, Inc. | Genetically-engineered chlorella or prototheca microbe and oil produced therefrom |
| CN103502461A (zh) | 2010-12-30 | 2014-01-08 | 纳幕尔杜邦公司 | 在含油酵母中通过提高yap1转录因子活性提高油含量 |
| BR112013016769A2 (pt) | 2010-12-30 | 2016-10-11 | Du Pont | yarrowia lipolytica transformada e método para produzir pelo menos um produto não nativo de interesse |
| CN110066836A (zh) | 2011-02-02 | 2019-07-30 | 柯碧恩生物技术公司 | 产自重组产油微生物的定制油 |
| US20130040340A1 (en) | 2011-02-07 | 2013-02-14 | E. I. Du Pont De Nemours And Company | Production of alcohol esters in situ using alcohols and fatty acids produced by microorganisms |
| JP6061866B2 (ja) * | 2011-02-11 | 2017-01-18 | イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニーE.I.Du Pont De Nemours And Company | 微生物バイオマスから脂質含有組成物を得る方法 |
| US8759044B2 (en) | 2011-03-23 | 2014-06-24 | Butamax Advanced Biofuels Llc | In situ expression of lipase for enzymatic production of alcohol esters during fermentation |
| US8765425B2 (en) | 2011-03-23 | 2014-07-01 | Butamax Advanced Biofuels Llc | In situ expression of lipase for enzymatic production of alcohol esters during fermentation |
| US8969049B2 (en) | 2011-03-31 | 2015-03-03 | E I Du Pont De Nemours And Company | Yarrowia diacylglycerol acyltransferase promoter regions for gene expression in yeast |
| US20120247066A1 (en) | 2011-04-01 | 2012-10-04 | Ice House America, Llc | Ice bagging apparatus and methods |
| EP2694665A1 (en) | 2011-04-01 | 2014-02-12 | E. I. Du Pont de Nemours and Company | Yarrowia esterase/lipase promoter regions for gene expression in yeast |
| WO2012138613A1 (en) | 2011-04-05 | 2012-10-11 | E. I. Du Pont De Nemours And Company | Yarrowia n-alkane-hydroxylating cytochrome p450 promoter regions for gene expression in yeast |
| EP2702148A1 (en) | 2011-04-07 | 2014-03-05 | E.I. Du Pont De Nemours And Company | Yarrowia peroxisomal 2,4-dienoyl-coa reductase promoter regions for gene expression in yeast |
| EP2714724A1 (en) | 2011-05-26 | 2014-04-09 | E. I. Du Pont de Nemours and Company | Expression of caleosin in recombinant oleaginous microorganisms to increase oil content therein |
| US8544772B2 (en) * | 2011-05-27 | 2013-10-01 | Ginn Mineral Technology, Inc. | Method for the recovery of minerals |
| CN105255738B (zh) * | 2011-07-21 | 2024-12-27 | 帝斯曼知识产权资产管理有限公司 | 生产二十碳五烯酸的微生物、脂肪酸组合物及其制作方法与用途 |
| EA035287B1 (ru) * | 2011-07-21 | 2020-05-25 | ДСМ АйПи АССЕТС Б.В. | Микроорганизмы, продуцирующие эйкозапентаеновую кислоту, композиции, содержащие жирные кислоты, и способы их получения и применения |
| ES2857173T3 (es) * | 2011-07-21 | 2021-09-28 | Dsm Ip Assets Bv | Aceites microbianos enriquecidos en ácidos grasos poliinsaturados |
| CN103031349B (zh) * | 2011-09-29 | 2014-07-09 | 私立辅仁大学 | 利用Cystofilobasidium属的酵母菌产生油脂的方法和系统 |
| BR112014025719A8 (pt) | 2012-04-18 | 2017-10-03 | Solazyme Inc | Óleos customizados |
| WO2013192007A1 (en) | 2012-06-19 | 2013-12-27 | E. I. Du Pont De Nemours And Company | MUTANT ACYL-CoA:LYSOPHOSPHATIDYLCHOLINE ACYLTRANSFERASES |
| CN102787128A (zh) * | 2012-08-28 | 2012-11-21 | 江南大学 | 一种用于多不饱和脂肪酸生物合成的脱饱和酶Δ9 Des |
| US9701989B2 (en) | 2012-12-21 | 2017-07-11 | E I Du Pont De Nemours And Company | Recombinant microbial cells that produce at least 28% eicosapentaenoic acid as dry cell weight |
| CA2892516A1 (en) | 2012-12-21 | 2014-06-26 | E. I. Du Pont De Nemours And Company | Down-regulation of a polynucleotide encoding a sou2 sorbitol utilization protein to modify lipid production in microbial cells |
| US10123986B2 (en) | 2012-12-24 | 2018-11-13 | Qualitas Health, Ltd. | Eicosapentaenoic acid (EPA) formulations |
| MX372724B (es) | 2012-12-24 | 2020-06-19 | Qualitas Health Inc | Formulaciones de acido eicosapentaenoico (epa). |
| US9629820B2 (en) | 2012-12-24 | 2017-04-25 | Qualitas Health, Ltd. | Eicosapentaenoic acid (EPA) formulations |
| CN105431529A (zh) | 2013-05-03 | 2016-03-23 | 德克萨斯大学系统董事会 | 用于真菌脂质生产的组合物和方法 |
| MX369685B (es) | 2013-10-04 | 2019-11-19 | Terravia Holdings Inc | Aceites adaptables. |
| CN103749744A (zh) * | 2014-02-24 | 2014-04-30 | 四川省三台县通宇食品有限公司 | 一种富含氨基酸食用菌油的制备方法 |
| EP3620517A3 (en) | 2014-07-10 | 2020-07-29 | Corbion Biotech, Inc. | Ketoacyl acp synthase genes and uses thereof |
| US10513711B2 (en) | 2014-08-13 | 2019-12-24 | Dupont Us Holding, Llc | Genetic targeting in non-conventional yeast using an RNA-guided endonuclease |
| IL241841B (en) * | 2014-09-30 | 2019-09-26 | Univ Free State | Production of proteins for human and animal health using yarrowia lipolytica |
| EP3626832B1 (en) * | 2014-11-25 | 2024-06-12 | The Brigham and Women's Hospital, Inc. | Method of identifying a person having a predisposition to or afflicted with a cardiometabolic disease |
| WO2016085876A1 (en) | 2014-11-25 | 2016-06-02 | The Broad Institute Inc. | Clonal haematopoiesis |
| US9682034B2 (en) | 2015-03-10 | 2017-06-20 | Elc Management Llc | Methods and compositions for treating skin to resolve inflammation and screening for actives that stimulate pro-resolution pathways |
| CN104805027B (zh) * | 2015-05-27 | 2018-04-27 | 天津大学 | 一种重组耶氏解脂酵母菌株及其构建方法和应用 |
| JP6898915B2 (ja) | 2015-07-22 | 2021-07-07 | イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニーE.I.Du Pont De Nemours And Company | 生物を用いる長鎖ジカルボン酸の高レベルの生産 |
| GB201602410D0 (en) | 2016-02-10 | 2016-03-23 | Tate & Lyle Ingredients | Methods for improving the gastrointestinal tolerance of food and beverage products comprising sweet, low-digestible carbohydrates |
| JP6897917B2 (ja) | 2015-10-01 | 2021-07-07 | ディーエスエム アイピー アセッツ ビー.ブイ.Dsm Ip Assets B.V. | ペットフードに用いるサプリメント素材 |
| FI4144844T3 (fi) | 2015-10-12 | 2025-11-24 | Dupont Us Holding Llc | Suojatut dna-templaatit geenimuokkaukseen ja homologisen rekombinaation lisäämiseen soluissa ja niiden käyttömenetelmät |
| CN106190872B (zh) * | 2016-09-23 | 2019-10-25 | 厦门大学 | 发酵罐底物流加生产二十二碳六烯酸的方法 |
| EP4159850A1 (en) | 2016-12-16 | 2023-04-05 | Danmarks Tekniske Universitet | Production of desaturated fatty alcohols and desaturated fatty alcohol acetates in yeast |
| WO2018109163A1 (en) | 2016-12-16 | 2018-06-21 | Danmarks Tekniske Universitet | Methods for producing fatty alcohols and derivatives thereof in yeast |
| EP3348647A1 (en) | 2017-01-13 | 2018-07-18 | Institut National De La Recherche Agronomique | Mutant yeast strain capable of producing medium chain fatty acids |
| CN108728477B (zh) * | 2017-04-24 | 2022-02-22 | 华东理工大学 | 一种高效的转座突变系统及构建方法 |
| CN107502601B (zh) * | 2017-06-13 | 2020-04-21 | 天津科技大学 | 一种胰蛋白酶抗性改良的脂肪酶突变体及其基因和应用 |
| WO2019143660A1 (en) * | 2018-01-16 | 2019-07-25 | Trustees Of Boston University | Clonal hematopoiesis and cytokine targets |
| US11913046B2 (en) | 2018-04-23 | 2024-02-27 | Inbiose N.V. | Increasing export of 2'fucosyllactose from microbial cells through the expression of a heterologous nucleic acid |
| MX2021008018A (es) | 2019-01-03 | 2021-12-10 | Corbion Biotech Inc | Procedimiento para la fabricacion de suspension de celulas lisadas. |
| CN110499259B (zh) * | 2019-07-22 | 2021-07-27 | 浙江工业大学 | 一种解酯耶氏酵母yw100-1及其应用 |
| US11572546B2 (en) | 2019-07-29 | 2023-02-07 | Ginkgo Bioworks, Inc. | Methods and compositions involving promoters derived from Yarrowia lipolytica |
| WO2022235655A1 (en) | 2021-05-04 | 2022-11-10 | Nutrition & Biosciences USA 4, Inc. | Compositions comprising insoluble alpha-glucan |
| US20240239921A1 (en) | 2021-05-04 | 2024-07-18 | Nutrition & Biosciences USA 4, Inc. | Compositions comprising oxidized insoluble alpha-glucan |
| EP4463519A1 (en) | 2022-01-12 | 2024-11-20 | Nutrition & Biosciences USA 4, Inc. | Coating compositions comprising rubber and insoluble alpha-glucan |
| CA3246295A1 (en) | 2022-03-21 | 2023-09-28 | Nutrition & Biosciences Usa 4 Inc | COMPOSITIONS CONTAINING AN INSOLUBLE ALPHA-GLUCANE |
| JP2025539450A (ja) * | 2022-12-02 | 2025-12-05 | マラ リニューアブルズ コーポレーション | 操作された脂質特性を有する油組成物及びその生成方法 |
| CN116121093B (zh) * | 2022-12-12 | 2025-11-07 | 浙江大学杭州国际科创中心 | 一种用于表达细胞色素p450的工程酵母菌株及其应用 |
| WO2025207802A1 (en) | 2024-03-27 | 2025-10-02 | Nutrition & Biosciences USA 4, Inc. | Recombinant microbial strains comprising reduced beta-oxidation phenotypes and methods thereof |
| CN118703533B (zh) * | 2024-08-01 | 2025-11-21 | 湖南农业大学 | OsGAT3基因在调控水稻Cd、Cu或Mn含量及株高中的应用 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2052564T3 (es) | 1986-07-08 | 1994-07-16 | Suntory Ltd | Procedimiento para la produccion de acido bishomo-gamma-linolenico y acido eicosapanteonico. |
| US5246841A (en) | 1986-12-26 | 1993-09-21 | Sagami Chemical Research Center | Microbial process for production of eicosapentaenoic acid |
| US5244921A (en) | 1990-03-21 | 1993-09-14 | Martek Corporation | Eicosapentaenoic acids and methods for their production |
| US5246842A (en) | 1991-10-30 | 1993-09-21 | The United States Of America As Represented By The Secretary Of Agriculture | Production of eicosapentaenoic acid from filamentous fungi utilizing lactose as a primary carbon source |
| DK0956013T3 (da) | 1996-10-11 | 2003-08-04 | Scarista Ltd | Farmaceutisk præparat indeholdende eicosapentaensyre og/eller stearidonsyre |
| US5968809A (en) | 1997-04-11 | 1999-10-19 | Abbot Laboratories | Methods and compositions for synthesis of long chain poly-unsaturated fatty acids |
| US6825017B1 (en) | 1998-12-07 | 2004-11-30 | Washington State University Research Foundation | Desaturases and methods of using them for synthesis of polyunsaturated fatty acids |
| EP1088552B1 (en) * | 1999-09-30 | 2006-04-19 | Loders Croklaan B.V. | Compositions containing pinolenic acid and its use a health component |
| EP1279400A1 (en) | 2001-07-25 | 2003-01-29 | Target Hit sa | Modifying the fatty acid composition of cell membranes of organs and tissues |
| US7410663B2 (en) | 2002-08-07 | 2008-08-12 | Kao Corporation | Oil or fat composition |
| WO2004018598A1 (ja) | 2002-08-07 | 2004-03-04 | Kao Corporation | 油脂組成物 |
| AU2003301007B2 (en) | 2002-12-20 | 2008-01-31 | The Procter & Gamble Company | Tufted laminate web |
| US7125672B2 (en) | 2003-05-07 | 2006-10-24 | E. I. Du Pont De Nemours And Company | Codon-optimized genes for the production of polyunsaturated fatty acids in oleaginous yeasts |
| US7238482B2 (en) * | 2003-05-07 | 2007-07-03 | E. I. Du Pont De Nemours And Company | Production of polyunsaturated fatty acids in oleaginous yeasts |
| US8313911B2 (en) * | 2003-05-07 | 2012-11-20 | E I Du Pont De Nemours And Company | Production of polyunsaturated fatty acids in oleaginous yeasts |
| US7214491B2 (en) | 2003-05-07 | 2007-05-08 | E. I. Du Pont De Nemours And Company | Δ-12 desaturase gene suitable for altering levels of polyunsaturated fatty acids in oleaginous yeasts |
| US7267976B2 (en) | 2003-07-02 | 2007-09-11 | E.I. Du Pont De Nemours And Company | Acyltransferases for alteration of polyunsaturated fatty acids and oil content in oleaginous yeasts |
| US7504259B2 (en) * | 2003-11-12 | 2009-03-17 | E. I. Du Pont De Nemours And Company | Δ12 desaturases suitable for altering levels of polyunsaturated fatty acids in oleaginous yeast |
| US7550651B2 (en) | 2004-06-25 | 2009-06-23 | E.I. Du Pont De Nemours And Company | Delta-8 desaturase and its use in making polyunsaturated fatty acids |
| US7465564B2 (en) | 2004-08-10 | 2008-12-16 | E.I. Du Pont De Nemours And Company | Production of γ-linolenic acid in oleaginous yeast |
| US7550286B2 (en) * | 2004-11-04 | 2009-06-23 | E. I. Du Pont De Nemours And Company | Docosahexaenoic acid producing strains of Yarrowia lipolytica |
| US8048652B2 (en) * | 2005-05-12 | 2011-11-01 | Martek Biosciences Corporation | Biomass hydrolysate and uses and production thereof |
| FR2888976B1 (fr) | 2005-07-25 | 2007-10-12 | Oberthur Card Syst Sa | Entite electronique avec moyens de communication par contact et a distance |
| WO2007061742A1 (en) | 2005-11-23 | 2007-05-31 | E. I. Du Pont De Nemours And Company | Delta-9 elongases and their use in making polyunsaturated fatty acids |
| US20070225370A1 (en) | 2006-03-21 | 2007-09-27 | Joar Opheim | Nutritional Compositions and Methods |
| US7943823B2 (en) | 2006-04-28 | 2011-05-17 | E.I. Du Pont De Nemours And Company | Delta-8 desaturase and its use in making polyunsaturated fatty acids |
| US7709239B2 (en) | 2006-12-07 | 2010-05-04 | E.I. Du Pont De Nemours And Company | Mutant Δ8 desaturase genes engineered by targeted mutagenesis and their use in making polyunsaturated fatty acids |
| DK2129777T3 (en) | 2007-04-03 | 2016-01-25 | Du Pont | MULTIZYMER AND USE THEREOF FOR THE PRODUCTION OF polyunsaturated fatty acids |
| US8188338B2 (en) * | 2007-04-10 | 2012-05-29 | E. I. Du Pont De Nemours And Company | Delta-8 desaturases and their use in making polyunsaturated fatty acids |
-
2008
- 2008-10-03 US US12/244,822 patent/US8323935B2/en active Active
- 2008-10-03 WO PCT/US2008/078642 patent/WO2009046231A1/en not_active Ceased
- 2008-10-03 EP EP08835977A patent/EP2195415A1/en not_active Withdrawn
- 2008-10-03 CN CN200880118875.4A patent/CN101970638B/zh not_active Expired - Fee Related
- 2008-10-03 JP JP2010528141A patent/JP5711968B2/ja not_active Expired - Fee Related
- 2008-10-03 US US12/244,950 patent/US20090117253A1/en not_active Abandoned
- 2008-10-03 CA CA2701094A patent/CA2701094A1/en not_active Abandoned
-
2012
- 2012-07-20 US US13/554,429 patent/US8735108B2/en active Active
-
2013
- 2013-02-28 US US13/780,532 patent/US8822185B2/en active Active
-
2014
- 2014-07-22 US US14/337,593 patent/US9617571B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20130230891A1 (en) | 2013-09-05 |
| US8822185B2 (en) | 2014-09-02 |
| WO2009046231A1 (en) | 2009-04-09 |
| US8323935B2 (en) | 2012-12-04 |
| CA2701094A1 (en) | 2009-04-09 |
| US20120289600A1 (en) | 2012-11-15 |
| JP2011501661A (ja) | 2011-01-13 |
| US8735108B2 (en) | 2014-05-27 |
| US9617571B2 (en) | 2017-04-11 |
| CN101970638B (zh) | 2015-02-11 |
| US20090117253A1 (en) | 2009-05-07 |
| CN101970638A (zh) | 2011-02-09 |
| EP2195415A1 (en) | 2010-06-16 |
| US20090093543A1 (en) | 2009-04-09 |
| US20150024441A1 (en) | 2015-01-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5711968B2 (ja) | 高エイコサペンタエン酸を生成するためのヤロウィア・リポリティカ(YarrowiaLipolytica)の最適化株 | |
| US8815566B2 (en) | High eicosapentaenoic acid producing strains of Yarrowia lipolytica | |
| US8637298B2 (en) | Optimized strains of yarrowia lipolytica for high eicosapentaenoic acid production | |
| JP2016101172A (ja) | 改良されたヤロウイア・リポリティカ(yarrowialipolytica)最適化株による高エイコサペンタエン酸油 | |
| JP2012530182A6 (ja) | 改良されたヤロウイア・リポリティカ(yarrowia lipolytica)最適化株による高エイコサペンタエン酸油 | |
| CN102803289B (zh) | 用于高水平生产二十碳五烯酸的改善的优化的解脂耶氏酵母菌株 | |
| JP2012529913A6 (ja) | エイコサペンタエン酸を高産生するよう改良されたヤロウイア・リポリティカ(Yarrowia lipolytica)最適化株 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110928 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20110928 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130917 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131203 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20140805 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141126 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20141203 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150210 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150309 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5711968 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |